BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, Zheng L, Chen MS, Shi M, Wei W, Guo RP. Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:167-76. [PMID: 33791252 DOI: 10.2147/JHC.S298538] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Pan J, Gao F, Xu W, Li H, Qi X. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Adv Ther 2022. [DOI: 10.1007/s12325-022-02371-3] [Reference Citation Analysis]
2 Wu Y, Zheng S, Zhang Z, Chen G, Chen X, Zheng T, Guo X, Chen H, Wang M, Xie X, Zhang B. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization. Medicina 2022;58:1343. [DOI: 10.3390/medicina58101343] [Reference Citation Analysis]
3 Xu Y, Fu S, Mao Y, Huang S, Li D, Wu J. Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Front Med 2022;9. [DOI: 10.3389/fmed.2022.919069] [Reference Citation Analysis]
4 Yi X, Fu Y, Long Q, Zhao Y, Li S, Zhou C, Lin H, Liu X, Liu C, Chen C, Shi L. Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy. Front Oncol 2022;12:892192. [PMID: 35651812 DOI: 10.3389/fonc.2022.892192] [Reference Citation Analysis]
5 Wu Y, Lin H, You X, Guo T, Sun T, Xu H, Fu X. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Front Oncol 2022;12:764923. [DOI: 10.3389/fonc.2022.764923] [Reference Citation Analysis]
6 Yuan J, Xu L, Zhou J, Shen L. Application of immune checkpoint inhibitors in hepatobiliary cancers. iLIVER 2022;1:43-48. [DOI: 10.1016/j.iliver.2022.03.002] [Reference Citation Analysis]
7 郭 宇. Progress in the Treatment of Hepatocellular Carcinoma Based on Hepatic Arterial Infusion Chemotherapy. ACM 2022;12:587-592. [DOI: 10.12677/acm.2022.121087] [Reference Citation Analysis]
8 Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Shi M, Li QJ. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211063848. [PMID: 34898313 DOI: 10.1177/15330338211063848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
10 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
11 Sun X, Mei J, Lin W, Yang Z, Peng W, Chen J, Zhang Y, Xu L, Chen M. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer 2021;21:775. [PMID: 34218801 DOI: 10.1186/s12885-021-08428-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]